Caladrius Biosciences Inc
CLBS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.35M
Close$
Share Statistics
| Market cap | $3.35 Million |
|---|---|
| Enterprise Value | $-7,091,632.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.91 |
| Beta | 0.91 |
| Outstanding Shares | 9,106,000 |
Return
| Return on Equity | -177.35% |
|---|---|
| Return on Assets | -132.59% |
| Return on Invested Capital | 52.85% |
Valuation & Multiples
| P/E Ratio | -0.65 |
|---|---|
| PEG | 1.74 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -70.92 |
| Enterprise Value to EBIT | -1.67 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Caladrius Biosciences Inc
CEO: David Mazzo Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mec...